A study by Australian microbiologists at Queensland, Melbourne and Griffiths universities has shown that the candidate neurodegenerative disease drug PBT-2, combined with a polymyxin antibiotic, induced potent antimicrobial activity against polymyxin-resistant gram-negative pathogens.
BEIJING – Sino-U.S. infectious diseases specialist Brii Biosciences Inc., with U.S. offices in Durham, N.C., and San Francisco, and China offices in Beijing and Shanghai, is bringing to greater China three investigational products from anti-infective therapy developer Qpex Biopharma Inc., of San Diego, to treat various multidrug-resistant gram-negative infections.
